Medlab secures export licence

Latest News

Medlab Clinical (ASX:MDC) says it has received a Licence to Export Cannabis from the Canberra-based Office of Drug Control (ODC).

The licence, which is renewable annually, relates to its two cannabis-based medicines, NanaBis and NanaBidial.

NanaBis is a whole plant 1:1 extract of CBD and THC. NanaBidial is a whole plant extract of CBD and THC (predominantly CBD). Both products utilise Medlab’s patented NanoCelle delivery platform. The platform allows the delivery of nanoparticles of the active pharmaceutical ingredients into the side of the cheek.

According to Medlab CEO, Dr Sean Hall, the licence will allow Medlab to undertake more formal overseas trade conversations with confidence in the knowledge that the Company can supply legally overseas. 

“This Licence is a welcome addition to our other approvals, allowing Medlab to research, manufacture, conduct research trials, supply within Australia, and now, pending the right partner, foreign markets,” he said.